Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alimera Sciences (ALIM)
NASDAQ:ALIM
Holding ALIM?
Track your performance easily
ALIM Stock Chart & Stats
Day’s Range$5.53 - $5.56
52-Week Range― - ―
Previous Close$5.55
Volume2.68M
Average Volume (3M)N/A
Market Cap
$301.29M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.75Price Target Upside3.79% Upside
Rating ConsensusHold
Number of Analyst Covering4
Alimera News
PremiumCompany Announcements
Alimera Merger: New Board, Stock Cancellation, and CVRs
PremiumCompany Announcements
Alimera Stockholders Approve Merger to Become Subsidiary
Bulls Say, Bears Say
Bulls Say
AcquisitionAlimera announced the signing of a definitive agreement to be acquired by ANI Pharmaceuticals for $5.50/share in cash upfront and contingent value rights worth up to $0.50/share.
Board ApprovalThe transaction has been approved by both Alimera’s and ANI Pharmaceuticals’ Board of Directors.
Debt RepaymentANI is repaying the $72.5M of debt Alimera currently holds.
Bears Say
Analyst DowngradeAnalyst downgrades ALIM shares to Hold, from Buy, and removes the prior 12-month price target.
Rating DowngradeGiven the price of ALIM shares after the announcement, the rating for ALIM has been downgraded to Neutral from Buy.
Revenue ContingencyPayments of CVR are contingent upon the achievement of $140M in net revenue on sales of ILUVIEN and YUTIQ for 2026.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALIM FAQ
What was Alimera Sciences’s price range in the past 12 months?
Currently, no data Available
What is Alimera Sciences’s market cap?
Currently, no data Available
When is Alimera Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alimera Sciences’s earnings last quarter?
Currently, no data Available
Is Alimera Sciences overvalued?
According to Wall Street analysts Alimera Sciences’s price is currently Undervalued.
Does Alimera Sciences pay dividends?
Alimera Sciences does not currently pay dividends.
What is Alimera Sciences’s EPS estimate?
Alimera Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alimera Sciences have?
Currently, no data Available
What happened to Alimera Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alimera Sciences?
Among the largest hedge funds holding Alimera Sciences’s share is Gamco Investors, Inc. ET AL. It holds Alimera Sciences’s shares valued at 144K.
---
Alimera Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (3.79% Upside)
$5.75 (3.79% Upside)
Blogger Sentiment
Bullish
ALIM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 25.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-34.57%
Trailing 12-Months
Asset Growth
-2.93%
Trailing 12-Months
Company Description
Alimera Sciences
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
---
ALIM Stock 12 Month Forecast
Average Price Target
$5.75
▲(3.79% Upside)
Technical Analysis
---